Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2001

View Archived Issues

Year 2000 at Genentech marked by significant progress on all fronts

Amgen and Genesis Pharma sign distribution agreement for ARANESP

Phase II trial of P-45 falls short of primary objective

Celgene and Novartis to collaborate on SERM research for osteoporosis

Antifungal and anticancer drug discovery alliance established by XTL and Dyax

British Biotech provides update on clinical development of marimastat

Hextend shows promise in preclinical studies as septic shock treatment

Second-generation retroviral BRCA1 vector for ovarian cancer has improved preclinical profile

Dual regulator of TNF-alpha and IL-10 production with potential in chronic inflammatory diseases

Licensing opportunity from NIH: methods for identifying treatments for granulocytopenia

Evidence points to newly identified protein as a missing link between obesity and diabetes

CI-1028: a direct thrombin inhibitor with oral antithrombotic efficacy

Oral formulation of Fludara now available in U.K.

Promising phase II results reported for Antegren in both MS and Crohn's disease

Spider venom-derived peptide blocks atrial fibrillation in work by U.S. university researchers

Pyrazines acting as inhibitors of cell adhesion molecule expression

PEG-Intron approved by FDA for chronic hepatitis C

Antioxidants prepared at French research institutes possess anti-HIV activity

Novel oral cancer treatments to be codeveloped by Celltech and Johnson & Johnson

New series of metabotropic glutamate receptor antagonists designed at NPS

Tricyclic compounds inhibiting Fab I in the GlaxoSmithKline pipeline

German university researchers identify new sphingomyelinase inhibitors

Compounds prepared at Taisho may be particularly useful in bone diseases

Agents for hyperlipidemia, arteriosclerosis and related disorders in development at Yamanouchi

Cangene's chickenpox vaccine approved in Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...